Post-operative radiotherapy for Ewing sarcoma: when, how and how much?
Postoperative radiotherapy in Ewing family of tumors has undergone continuous evolution over the last few decades to establish its role in the combined modality management of these tumors. The process of evolution is still far from over. This review analyzes the evidence from major multi-institutional prospective trials as well as large retrospective institutional series in Ewing tumors to determine the current standards and controversies in postoperative radiation. The indications of PORT, radiation dose-fractionation, timing, target volumes and treatment planning, as well as the late effects are reviewed. A summary of evidence based consensus is presented and unresolved aspects are discussed. Pediatr Blood Cancer 2008;51:575-580. (c) 2008 Wiley-Liss, Inc.
Department of Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai 400012, India. laskars2000@yahoo.com
S
S
Laskar
I
I
Mallick
T
T
Gupta
M A
MA
Muckaden
D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D019317:Evidence-Based Medicine; D006801:Humans; D011184:Postoperative Period; D018714:Radiotherapy, Adjuvant; D012512:Sarcoma, Ewing / Q000532:radiotherapy* / Q000601:surgery